A randomized, double-blind, placebo-controlled trial in Nature Communications tested whether losartan and prednisolone could affect post-COVID syndrome and markers of cardiac inflammation. The study, led by Victor O. Puntmann and Eike Nagel, evaluated two widely used drugs with different mechanisms in the context of persistent cardiometabolic and inflammatory signals after SARS-CoV-2 infection. The trial design targeted both symptom outcomes consistent with post-acute sequelae and objective readouts of cardiac inflammation. By using an established antihypertensive (losartan) and an anti-inflammatory steroid (prednisolone), the study aimed to determine whether modulation of inflammation and vascular signaling could translate into clinically meaningful changes. The full results and effect sizes determine whether these repurposed options remain viable for post-COVID care pathways or whether further trial refinement is needed. Regardless, the work highlights ongoing clinical scrutiny of post-COVID sequelae beyond respiratory recovery.